Clin Cancer Res: clinical trials confirm that new breast cancer drugs can treat glioblastoma

August 17, 2019 / BIOON / - Ivy brain tumor center of Barrow Neurological Institute (BNI) released the results of the latest clinical trial, which used the breast cancer drug ribociclib (kisquali) to treat recurrent glioblastoma The drug, recently approved by the FDA for the treatment of advanced breast cancer, is part of a newly discovered targeted therapy that destroys cancer cell division and could become a major component of a new drug cocktail for patients with malignant brain tumors, such as glioblastoma "Glioblastoma presents a unique and complex challenge compared to other types of cancer," said Dr Nader Sanai, director of ivy brain cancer center "You're not facing a single entity, but a set of patient specific genetic variations This phase 0 trial uses a precise medical approach to reveal which types of glioblastomas may respond to ribociclib and how our patients' tumors are resistant to this new treatment "Image source: Ivy brain tumor center experimental results show that ribociclib has a unique ability to break through the blood-brain barrier Blood brain barrier (BBB) is a key obstacle to drug development of brain tumor patients for many years, and this drug can effectively hit the molecular targets in cancer cells The clinical trial design also identified a potential drug resistance mechanism, which is being used by the Ivy brain tumor center clinical trial team to conduct drug cocktail trials in patients with recurrent glioblastoma "This comprehensive study has helped us to identify an effective combination of drugs to destroy the mechanism of resistance of glioblastoma to ribociclib In less than a year, we have made great progress in the development of a new cocktail drug, which is of great significance considering how valuable the time for patients and doctors to fight against the disease is "The results were published in the journal Clinical Cancer Research, published by the American Cancer Research Association Reference: an Chi Tien et al, a phase 0 trial of ribociclib in recurrent glioblastoma patients integrating a tumor pharmaceutical - and pharmaceutical guided expansion cohort, clinical cancer research (2019) Doi: 10.1158/1078-0432.ccr-19-0133